R
Robert A. Cherny
Researcher at Florey Institute of Neuroscience and Mental Health
Publications - 116
Citations - 16493
Robert A. Cherny is an academic researcher from Florey Institute of Neuroscience and Mental Health. The author has contributed to research in topics: Neurodegeneration & Amyloid beta. The author has an hindex of 56, co-authored 116 publications receiving 15410 citations. Previous affiliations of Robert A. Cherny include Harvard University & Mental Health Research Institute.
Papers
More filters
Journal ArticleDOI
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.
Catriona McLean,Robert A. Cherny,Fiona W. Fraser,Stephanie J. Fuller,Margaret J. Smith,Konrad Beyreuther,Ashley I. Bush,Ashley I. Bush,Colin L. Masters +8 more
TL;DR: The genetic evidence strongly supports the view that Aβ amyloid production is central to the cause of Alzheimer's disease, and the concept of several interacting pools of Aβ, that is, a large relatively static insoluble pool that is derived from a constantly turning over smaller soluble pool, is supported.
Journal ArticleDOI
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
Robert A. Cherny,Craig S. Atwood,Michel Xilinas,Danielle N. Gray,Walton D. Jones,Catriona McLean,Kevin J. Barnham,Irene Volitakis,Fiona W. Fraser,Young-Seon Kim,Xudong Huang,Lee E. Goldstein,Robert D. Moir,James Lim,Konrad Beyreuther,Hui Zheng,Rudolph E. Tanzi,Colin L. Masters,Ashley I. Bush,Ashley I. Bush +19 more
TL;DR: A 49% decrease in brain Abeta deposition is reported in a blinded study of APP2576 transgenic mice treated orally for 9 weeks with clioquinol, an antibiotic and bioavailable Cu/Zn chelator, support targeting the interactions of Cu and Zn with Abeta as a novel therapy for the prevention and treatment of AD.
Journal ArticleDOI
Metal-Protein Attenuation With Iodochlorhydroxyquin (Clioquinol) Targeting Aβ Amyloid Deposition and Toxicity in Alzheimer Disease: A Pilot Phase 2 Clinical Trial
Craig W. Ritchie,Ashley I. Bush,Andrew Mackinnon,Steve Macfarlane,Maree Mastwyk,Lachlan MacGregor,Lyn Kiers,Robert A. Cherny,Qiao-Xin Li,Amanda Tammer,Darryl Carrington,Christine Mavros,Irene Volitakis,Michel Xilinas,David Ames,Stephen M. Davis,Konrad Beyreuther,Rudolph E. Tanzi,Colin L. Masters +18 more
TL;DR: This pilot phase 2 study supports further investigation of this novel treatment strategy using a metal-protein-attenuating compound, and the effect of treatment was significant in the more severely affected group.
Journal ArticleDOI
Alzheimer's Disease Amyloid-β Binds Copper and Zinc to Generate an Allosterically Ordered Membrane-penetrating Structure Containing Superoxide Dismutase-like Subunits
Cyril C. Curtain,Feda Ali,Irene Volitakis,Robert A. Cherny,Raymond S. Norton,Konrad Beyreuther,Colin J. Barrow,Colin L. Masters,Ashley I. Bush,Kevin Barnham +9 more
TL;DR: In this paper, it was shown that metal binding to Aβ generated an allosterically ordered membrane-penetrating oligomer linked by superoxide dismutase-like bridging histidine residues.
Journal ArticleDOI
Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ
Paul A. Adlard,Robert A. Cherny,Robert A. Cherny,David Finkelstein,David Finkelstein,Elisabeth Gautier,Elysia Robb,Mikhalina Cortes,Irene Volitakis,Xiang Liu,Jeffrey P. Smith,Keyla Perez,Keyla Perez,Katrina M. Laughton,Katrina M. Laughton,Qiao-Xin Li,Qiao-Xin Li,Susan A. Charman,Joseph A. Nicolazzo,Simon Wilkins,Simon Wilkins,Karolina Deleva,Toni Lynch,Gaik Beng Kok,Craig W. Ritchie,Rudolph E. Tanzi,Roberto Cappai,Roberto Cappai,Colin L. Masters,Colin L. Masters,Kevin J. Barnham,Kevin J. Barnham,Ashley I. Bush,Ashley I. Bush +33 more
TL;DR: The current data demonstrate that ionophore activity, inhibition of in vitro metal-mediated Abeta reactions, and blood-brain barrier permeability are indices that predict a potential disease-modifying drug for AD.